汇聚群英智慧，闪亮你我星光
Together, Spark Biomedicine!
各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的生物医药领域大事件。
本月热点
TOPICS
Revolution Medicines presents initial data from RMC-9805 monotherapy in patients with advanced pancreatic ductal adenocarcinoma； Novocure receives FDA approval for their electric field therapy in metastatic lung cancer; Zai Lab's DLL3-targeted ADC (ZL-1310) demonstrates promising ORRs and safety in extensive-stage SCLC; Vera announces Atacicept phase 2b study data of IgA nephropathy at ASN and follow-on raise of $300M; Otsuka’s anti-APRIL sibeprenlimab shows promise in Phase 3 IgA nephropathy trial； Amgen presents positive phase 3 data for Uplizna in myasthenia gravis at AANEM Annual Meeting; GSK acquires CD19/CD20/CD3 antibody from Chimagen Biosciences with $300M upfront；
Intellia’s in vivo CRISPR-based therapy reduces swelling attacks by 81% in phase 2 trial for hereditary angioedema; Results from Pfizer’s AAV gene therapy for Duchenne muscular dystrophy raise questions on microdystrophin as a surrogate endpoint; Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in DMD; News in oligonucleotide therapeutics: two siRNA startups;
Scholar Rock's apitegromab for spinal muscular atrophy succeeds in a late-stage study；
FDA Approves Pfizer's Hympavzi for Hemophilia A & B;
Lundbeck to acquire neurology-focused Longboard Pharmaceuticals in a $2.6B deal.
活动详情
主题：Monthly biotech news discussion - October 2024 in review
时间：2024年11月02日 Sat 9:00 PM（EST）/ 2024年11月03日 周日 早上9:00 AM（北京时间）
嘉宾：
Stephen Yan (严顺飞), BD Search & Evaluation @ AstraZeneca
(https://www.linkedin.com/in/shunfei-yan/)
Yanran He (何嫣然), Investment Director @ Sinopharm-CICC
(https://www.linkedin.cn/injobs/in/yanranhe)
Qinghong Yan (晏庆红), CEO @ Riboway Therapeutics
(http://linkedin.com/in/qinghong-yan)
Leon 'Jun' TANG (唐钧), Founding Partner @ InScienceWeTrust BioAdvisory
(https://www.linkedin.com/in/leontangnyc/)
Charlene Liao (廖晓伶), CEO @ Immune-Onc Therapeutics, Inc. (http://linkedin.com/in/charlene-liao-a1872a55)
Haoran Wang(王浩然), CEO @ Neoland Biosciences Co.,Ltd.
(https://www.linkedin.com/in/hao-ran-wang-228648b)
Xianbo Zhou(周显波), Founder & CEO @ AstraNeura
(https://www.linkedin.com/in/xianbo-zhou-7b33b76/)
Ethan Xu (徐亦迅),VP of Bioinformatics @ Aspen Neuroscience
(http://linkedin.com/in/ethan-yixun-xu-2b915a4)
Wenjun Wu (Armstrong,吴文君), Director @ HanKang Venture
(https://www.linkedin.com/in/文君-吴-14787b95/)
本期活动组织：Ethan Xu & Stephen Yan
本月热点总结：Armstrong和monthly news嘉宾
活动直播伙伴
About us
BioSpark
BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。
BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.
成为BioSpark会员：BioSpark期待您的加入--会员推荐与申请
Follow us on Twitter:
https://twitter.com/BioSpark_Group
Follow us on LinkedIn:
https://www.linkedin.com/company/biospark-group
BioSpark events Calendar:
https://tinyurl.com/tcwy44t6
Email us: info@BioSpark.org
合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group
赞 助 机 构
战 略 合 作
BioSpark Group致力于建立华人在生物医领域的生态系统和互助网络，立足于波士顿，我们在硅谷和中国与ISWC、医药笔记和MITCEO 达成战略合作。
封面图来源：123rf
复宏汉霖「地舒单抗」上市申请获FDA受理！
国产自免新药之光！恒瑞的「夫那奇珠单抗」疗效到底怎么样？
礼来公布「重磅自免药物」长期数据，对战强生、艾伯维！
